Abstract Clinical improvement during pregnancy in multiple sclerosis (MS) 
Introduction
Multiple sclerosis (MS) (Abramsky) is an autoimmune inflammatory disease of the brain and spinal cord characterized by demyelination and chronic neurodegeneration (Compston and Coles 2008) . Although the incidence of MS is higher in women, it shows clinical improvement during pregnancy, followed by temporary post-partum exacerbations (Abramsky 1994; Confavreux et al. 1998) . It is widely accepted that sex hormones have immune-regulatory activity and may prevent relapses in multiple sclerosis during pregnancy. Indeed, treatment with pregnancy levels of estrogen reduced disease severity and CNS lesions (Offner and Polanczyk 2006) in experimental autoimmune encephalomyelitis (EAE), an induced autoimmune disease of mice that mimics MS in susceptibility and histopathology (Maugh 1977) ,.
Previous studies have demonstrated that B cells may contribute to EAE pathogenesis. Although not essential for EAE induction, myelin oligodendrocyte glycoprotein (MOG)-specific antibodies enhance demyelination and inflammation in EAE (Linington et al. 1988; Lyons et al. 1999 ). In addition, MOG-specific B cells have been shown to function as antigen presenting cells (APCs) during the initiation of EAE (Bettelli et al. 2006) . However, despite their demonstrably inflammatory activity, B cells may have a more nuanced role in EAE pathogenesis.
There is accumulating evidence that regulatory B lymphocytes (B regs ) play an important role in limiting disease progression by suppressing inflammation in the CNS and reducing the number of infiltrating pro-inflammatory cells (Fillatreau et al. 2002; Wolf et al. 1996) . Studies addressing this phenomenon have identified phenotypically distinct subsets of IL-10 producing regulatory B cells including CD19 hi that exert immunosuppressive activity in vivo as well as in vitro (Evans et al. 2007; Matsumoto et al. 2014; Matsushita et al. 2008; Mauri and Bosma 2012) . Pivotal to regulatory B cell function is IL10, which inhibits production of pro-inflammatory cytokines by leukocytes and supports the differentiation and activation of CD4 + Foxp3 + regulatory T cells (T regs ) (Weber et al. 2007) .
Our previous studies suggested that the protection induced by 17β-estradiol (E2) against EAE in the absence of T regs included the induction of CD1d hi CD5
+ regulatory B cells (B regs ). In addition, we have shown that programmed death receptor-1 (PD-1) expression is increased on T regs in B cell replenished, E2 treated B cell-deficient (μMT −/− ) mice with EAE (Bodhankar et al. 2012; Subramanian et al. 2011) . These findings pointed to B regs as key players in potentiating additional T reg mediated neuroprotection during EAE. Furthermore, we recently demonstrated that E2 associated protection was mitigated in B cell deficient mice with EAE, but could be restored by replenishment of splenic B cells. (Bodhankar et al. 2011) . However, the protective effect of B cell transfers from immunized wild type (WT) mice was short-lived and the disease progressed in recipients from day 21 after immunization onwards (Bodhankar et al. 2012) . Parallel studies from our lab have also shown that IL-10 producing regulatory B cells limit CNS inflammation following experimental stroke (Bodhankar et al. 2013a) . While the role of B regs in down-regulating inflammatory reactions has been suggested in autoimmune diseases such as MS and Systemic Lupus Erythematosus (Mohrs et al.) (Blair et al. 2010; Duddy et al. 2007; Mauri and Bosma 2012) , it remained unclear what part they play in E2-confered protection against EAE. Our present findings demonstrate that IL-10 + B cells (B regs) are indispensable to E2-dependent amelioration of EAE neuro-inflammation, facilitating the recruitment of T regs to the inflamed CNS and upregulating expression of PD-1/PD-L1 signaling molecules.
Materials and methods

Animals
B cell deficient (μMT −/− ) mice were obtained from Jackson Laboratories (Bar Harbor, ME) and bred at the Animal Resource Facility at the VA Portland Health Care System (VAPHCS). Briefly, the μMT −/− strain was generated though targeted disruption of the membrane exon of the immunoglobulin μ chain gene, leading to the absence of mature B cells, and is maintained on a C57BL/6 background. 7-8 week old females were used for this study. IL-10 transcriptional reporter mice were obtained from Dr. Christopher Karp, Division of Molecular Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio. The generation and characterization of these mice has been described (Madan et al. 2009 ). The IL-10-GFP reporter mice have a floxed neomycin-IRES eGFP cassette inserted between the endogenous stop site and the poly (A) site of the Il-10 gene to help track IL-10 producing cells in vivo. The mice (designated as Vert-X) are homozygous, develop normally and are viable and fertile without any obvious abnormal phenotype (Mohrs et al. 2001) .
All animals were housed in the Animal Resource Facility at the VAPHCS in accordance with institutional guidelines. This study was conducted in accordance with National Institutes of Health guidelines for the use of experimental animals and the VAPHCS Animal Care and Use Committee approved all protocols.
Hormone treatment and induction of EAE All mice were monitored daily for clinical signs of disease and scored using the following scale: 0=normal; 1=limp tail or mild hind limb weakness; 2=moderate hind limb weakness or mild ataxia; 3=moderately severe hind limb weakness; 4= severe hind limb weakness or mild forelimb weakness or moderate ataxia; 5=paraplegia with no more than moderate forelimb weakness; and 6=paraplegia with severe forelimb weakness or severe ataxia or moribund condition. Mice were scored daily and were evaluated for incidence, day of onset, day of maximal clinical signs (peak) and total disease score over the course of the experiment (Cumulative Disease Index, CDI). Mean ± SEM were calculated for these parameters for each experimental group.
Histopathology
Intact spinal columns removed from mice at the end of the study (i.e. Day 24 post-immunization) were fixed in 4 % paraformaldehyde (PFA, eBioscience, San Diego, CA) then extricated from surrounding bone tissue. Dissected spinal cords were embedded in paraffin before sectioning. Ten μm thick slices were stained with hematoxylin and eosin to evaluate inflammatory lesions or stained using a Luxol Fast Blue (LFB) protocol to assess demyelination. Slides were imaged by light microscopy.
Isolation of leukocytes from spleen, spinal cord, and brain Immediately prior to transcardial perfusion with RPMI 1640 (Corning Cellgro, Manassas, VA), spleens were removed from animals under sterile conditions and single cell suspensions of leukocytes were prepared by disaggregation of the tissue through a 100 μm nylon mesh (BD Falcon, Bedford, MA). Cells were washed once with RPMI 1640 supplemented with 10 % fetal bovine serum (FBS, Thermo Scientific, Waltham, MA), then incubated with RBC Lysis Buffer (eBioscience) for 1 min to remove red cells, and washed in RPMI 1640+FBS. Cells were enumerated in a 1:1 dilution with 0.2 % trypan blue stain (Life Technologies, Grand Island, NY) using a Cellometer Auto T4 Cell Viability Counter (Nexcelom, Lawrence, MA), washed, and resuspended at 10 7 cells/ mL in stimulation medium (RPMI 1640 containing 10 % FBS, 1 % sodium pyruvate (Life Technologies), 1 % L-glutamine (Thermo Scientific), and 0.4 % β-mercaptoethanol (ME)(Sigma-Aldrich)).
Brains and spinal cords were passed through 100 μm mesh screens and washed as above. Cells were resuspended in 80 % Percoll (GE Healthcare, Pittsburgh, PA) then overlaid with 40 % Percoll to establish a density gradient and centrifuged at 1,600 rpm for 30 min following a method previously described (Campanella et al. 2002) . Leukocytes were collected from the resultant interface, counted, and resuspended in stimulation media for assay.
Flow cytometry
Single Cell suspensions were prepared as above then washed and resuspended in staining medium (phosphate buffered saline (PBS, Fisher Scientific, Fair Lawn, NJ), 0.5 % bovine serum albumin (BSA, Sigma-Aldrich), and 0.02 % sodium azide (Sigma-Aldrich). Leukocytes were labeled with a combination of the following antibodies obtained from BD Biosciences (San Jose, CA): PE-Cy7 CD4 (L3T4), APC CD8 (53-6.7), APC CD80 (16-10A1), PE I-A b (AF6-120.1), PE PD-1 (J43), APC CXCR5 (2G8), APC CD19 (1D3), PE CD1d (1B1), PerCP CD5 (53-7.3), PE PD-L1 (MIH5), PerCP-Cy5.5 CD11b (M1/70), PE CD45 (30-F11), PE CD62L (MEL-14), APC CD44 (IM7), PE CD122 (TM-β1), APC IFN-γ (XMG1.2), PE IL-17 (TC11-18H10), PE IgG 1 ,κ (R3-34), APC IgG 1 ,κ (A85-1). Intracellular staining of Foxp3 (MF23) was completed following overnight incubation in fixation/permeabilization buffer (BD Biosciences). Data were acquired using a BD Accuri C6 (BD Biosciences) using BD's proprietary C6 software.
Intracellular staining was visualized using a published immunofluorescence protocol (Subramanian et al. 2011) . Briefly, 2×10
6 cells were incubated in 1 mL of stimulation medium (as above) with phorbol 12-myristate 13-acetate (PMA, 50 ng/mL, Sigma-Aldrich), ionomycin (500 ng/mL, Sigma-Aldrich) and Brefeldin A (10 μg/mL, BD Biosciences) at 37°C and 5 % CO 2 . For intracellular IL-10 detection, 10 μg/mL lipopolysaccharide from E. coli (055:B5, Sigma-Aldrich) was added to the above cocktail .
Following incubation, Fc receptors were blocked with anti-CD16/32 monoclonal antibodies (mAb) (2.3G2; BD Biosciences) before cell surface staining, fixed in 4 % PFA (eBioscience), and permeabilized with Fixation/ Permeabilization buffer (BD Biosciences) according to the manufacturer's instructions. Permeabilized cells were washed with 1X Perm/Wash Buffer (BD Biosciences) and were stained with anti-IL-17, anti-TNFα, or anti-IFN-γ mAb. Isotype-matched mAb served as negative controls to demonstrate specificity and to establish background for the levels of IL-17, TNFα or IFN-γ expression.
Cell sorting and adoptive transfer of B cells
Age matched female IL-10 GFP + reporter B cell donors were immunized with 200 μg MOG 35-55 peptide (PolyPeptide Laboratories) in 200 μg CFA (as above). Ptx was not given to ensure the retention of MOG-primed cells in the spleens. Donor B cells were acquired on day 14 post immunization and splenic CD19 + B cells were purified using paramagnetic beadconjugated antibodies (Abs) from the Miltenyi B cell isolation kit and subsequently separated by AutoMACS (both from Miltenyi Biotec, Auburn, CA).
The negative fraction of the cells thus separated were CD19 + B cells with a purity of≥95 %. CD19 + B cells were suspended in stimulation medium (described above) and cultured in the presence of 1 μg/mL LPS (from E. coli serotype 055:B5) (Sigma-Adrich) for 48 h at 37°C, 5 % CO 2 and 95 % humidity. After culture, B cells were harvested from culture plates, washed free of LPS, and viable cells were counted. The cells were then resuspended at 10 8 purified IL-10-GFP+ B cells/mL in 0.9 % sodium chloride irrigation solution (saline, Baxter, Deerfield, IL) and 100 μL of either cell suspension (10 7 cells) or saline were transferred intravenously (i.v.) via tail vein into μMT −/− recipients on day 3 post MOG/CFA immunization. 
Results
Regulatory B cells require E2 to ameliorate clinical signs of EAE
We have reported previously that μMT −/− mice lost sustained clinical benefit from E2 during EAE, and that reconstitution with B cells from immunized donors restored E2-imparted protection (Bodhankar et al. 2012) . In the present study, we confirmed that not only are B cells required to establish protection with E2, but that the IL-10 + regulatory B cells (B regs ) are also able to suppress clinical signs of EAE in the presence of E2. While mice given E2 in conjunction with either treatment displayed delayed onset of disease, clinical manifestations of EAE were present in only 30 % (7 out of 23, Table 1 ) of E2-implanted μMT −/− mice that were the recipients of IL-10 producing B cells (E2/B regs group) compared to 63 % (12 out of 19, Table 1 ) of mice treated with E2 alone (E2/saline group) and 92 % (11 out of 12, Table 1 ) of mice that received only B regs (sham/ B regs group ) . Additionally, the cumulative disease index (CDI) and disease peak of mice given E2 and B regs were significantly lower than all other treatment groups (Table 1) . Importantly, mice given B regs but not E2 displayed no statistically significant differences in any of the clinical parameters evaluated compared to the control group. These data suggest that IL-10 producing B regs are not sufficient to protect against EAE in μMT −/− recipients independent of E2 signaling.
IL-10 producing B cells in combination with E2 treatment inhibits infiltration of leukocytes into the CNS of μMT −/− mice To evaluate the potential regulatory effects of B regs on monocyte and T cell activation, we first enumerated the number of leukocytes present in the spinal cord, brain, and spleen. Treatment with B regs in E2-implanted mice significantly reduced the number of infiltrating leukocytes in the spinal cord compared to the E2 only mice (Fig. 1a) . Notably, treatment with E2, B regs or both agents also significantly reduced the number of cells isolated from brains (Fig. 1b) . These results suggest that IL-10 producing B cells exposed to E2 limit leukocyte infiltration into the CNS of μMT −/− mice during EAE.
These data were supported by histological examination of spinal cord sections from experimental animals. Staining was performed using hematoxylin & eosin to assess the distribution of infiltrating cells and Luxol Fast Blue (LFB) to visualize demyelination. Sections from mice given saline, B regs or E2 alone demonstrated massive leukocyte infiltration with several foci of inflammation (indicated by arrows, Fig. 2a ) accompanied by extensive demyelination (Fig. 2b) . However, treatment with E2 together with B regs noticeably reduced both infiltrating cells and demyelinated lesions compared to the other treatment groups. These observations were consistent with the amelioration of EAE signs seen in groups given E2 and B regs and suggest that IL-10 + B cells arrest trafficking of leukocytes into the CNS in the presence of E2.
CNS infiltrating T lymphocytes are significantly reduced in μMT −/− mice treated with E2 and IL-10 producing B cells
Infiltrating leukocytes isolated from the spinal cords and brains of experimental animals were characterized in order to assess cells associated with clinical signs of disease. We observed a profound reduction in the number of infiltrating CD4 + T cells in the CNS of mice that received both E2 and IL-10 + B cells compared to either agent alone (Fig. 3a, b) . CD8 + T cells were also significantly less frequent in the spinal cords of treated mice, but this effect was also observed after administration of B regs or E2 alone (Fig. 3c) . Interestingly, only therapy with E2 and B regs caused a statistically significant decrease in the number of CD8 + T cells in the brains of mice with EAE (Fig. 3d) .
Previous reports indicated that activated CD4 + T cells, especially IL-17 producing CD4 + T cells, play a pathogenic role (Fig. 2a) and with Luxol Fast Blue to visualize extent of demyelination (Fig. 2b) . Arrows denote foci of inflammation. Magnification was 50× and 200× (inset). Sections are representative of 2 experiments (n=3 mice/group/experiment) Fig. 1 IL-10 producing B cells and E2 treatment reduce infiltration of leukocytes into the CNS of μMT −/− mice. Mononuclear cells were isolated from CNS tissues and total live cell numbers from spinal cords (Fig. 1a) and brains (Fig. 1b) were counted on a hemocytometer. Data shown are representative of 4 independent experiments consisting of 6 mice per group (mean ± SEM). Statistical analysis was performed with ANOVA followed by Newman-Kuels post hoc test. Significant differences between sample means are indicated (*p≤0.05; **p≤0.01; ***p≤ 0.001) recipients were not different compared to controls (10.8 % E2/ B regs vs. 9.5 % sham/saline, data not shown). Taken together, these results suggest that IL-10 producing B cells require E2 to reduce the infiltration of pathogenic immune cells into the CNS during EAE.
IL-10
+ B cells induce microglial quiescence in the presence of E2 during EAE Microglia are the primary immune effector cells in the CNS, which are capable of responding to a vast array of challenges and undergo phenotypic or morphological transformations upon encountering infection or injury. They are involved in almost all neuropathological conditions such as degenerative diseases, stroke, tumors, and traumatic brain injury (Nayak et al. 2014) . Reactive microglia/macrophages make up the majority of cells in multiple sclerosis plaques (Carson 2002) and act as APCs by expressing MHC class I, MHC class II and co-stimulatory molecules (Becher and Antel 1996) .
In the present study, we found that treatment with E2 or B regs individually caused a limited but significant reduction in the number of CD11b + CD45 hi activated microglia/ macrophages in the CNS of EAE-induced mice (Fig. 4a, b) . However, concurrent administration of B regs and E2 led to profound suppression in the percentage of activated microglia/macrophages compared to control (sham/saline), E2 only (E2/saline), and B regs only (sham/B regs ) treated groups (Fig. 4a, b) . Conversely, the proportion of resting microglia/ macrophages (CD11b + CD45 low ) was significantly increased in the E2/B regs treated group (Fig. 4c, d (Weber et al. 2007 ). Additionally, CD80 expression by CD11b + monocytes has been shown to play a critical part in the suppression of antigen-specific immune responses (Yang et al. 2006) .
Our results showed that treatment with B regs and E2 significantly increased the expression of I-A b on CD11b + monocytes in the spleen when compared to other groups (Fig. 5a ). We also found that monocyte expression of CD80 was significantly increased in E2 treated groups with or without B cells (Fig. 5b) . Further evaluation of the expression of the pro-inflammatory cytokine, TNF-α, in splenic monocytes indicated no significant differences in the number of TNFα + CD11b + cells in the spleen amongst experimental groups (Fig. 5c ). (Fig. 3a, b) and CD8 + T cells (Fig. 3c, d) were determined in individual spinal cords and brains and indicate the percentages of total gated live leukocytes (n=6). Data are representative of 4 independent experiments consisting of 6 mice per group (mean±SEM). Statistical analysis was performed with ANOVA followed by Newman-Kuels post hoc test. (Bodhankar et al. 2011 (Bodhankar et al. , 2013b . These results suggested that PD-L1 is a critical co-inhibitory molecule in E2-mediated protection against EAE.
Our current study explored whether the protection induced by E2 and IL-10 + B cells was mediated in part by regulatory T cells and the PD-1/PD-L1 pathway. Our data confirm that PD-L1 + CD11b
+ monocytes were enriched in the spleen of E2/B reg treated recipients versus control mice and B reg alone treated mice (Fig. 6a) . In contrast, there was no significant difference (Fig. 5a ) and CD80 (Fig. 5b) were determined on CD11b + splenocytes from the various treatment groups. Fig. 5c : TNF-α producing CD11b + monocytes. Data are representative of 4 independent experiments consisting of 6 mice per group (mean±SEM). Statistical analysis was performed with ANOVA followed by Newman-Kuels post hoc test. Significant differences between sample means are indicated (*p≤0.05; **p≤0.01; ***p≤0.001) Fig. 4 Administration of IL-10 producing B cells in combination with E2 treatment decreased activation of microglia/ macrophages in the CNS. CD11b
hi activated microglia/macrophages (Fig. 4a,  b) and CD11b + CD45 low resting microglia/macrophages (Fig. 4c,  d) were determined in individual spinal cords and brains. Data shown are representative of 4 independent experiments consisting of 6 mice per group (mean±SEM). Statistical analysis was performed with ANOVA followed by Newman-Kuels post hoc test. Significant differences between sample means are indicated (*p≤0.05; **p≤0.01; ***p≤0.001) in the expression of PD-L2 + CD11b + monocytes (data not shown). This finding is consistent with our previously published studies (Bodhankar et al. 2013b) .
Recently, CD8 + CD122 + regulatory T cells have been identified (Rifa'i et al. 2004; Rifa'i et al. 2008 ) that effectively suppress the proliferation and IFN-γ production in both CD8 + and CD4 + T cells through production of IL-10. Our results suggest that CD8 + CD122
+ are increased in the periphery of mice exposed to E2, although not in a statistically significant way (Fig. 6b) . In contrast, CD4 +
Foxp3
+ T cells were significantly enriched in the spleens of mice treated with IL-10 + B cells (Fig. 6c) . Interestingly, this effect appeared to be independent of E2 treatment. Examining PD-1 + T regs from each group, we found that only T regs from E2/B reg treated mice exhibited significantly higher levels of PD-1 compared to control groups (Fig. 6d) , suggesting a role for this cell type in E2/ PD-L1 mediated protection.
Cumulatively, these data indicate that IL-10 producing B cells in combination with E2 treatment increases the proportion of CD4 +
+ regulatory T cells and emphasizes the PD-1/PD-L1 signaling pathway's involvement in protection against EAE in B-cell deficient μMT −/− mice.
Discussion
Multiple sclerosis is a debilitating autoimmune disease of the central nervous system. Activation of auto-reactive T cells and increased secretion of inflammatory and neurotoxic factors by microglia leads to demyelination in the CNS (Chabot and Yong 2000; Malpass 2012; Steinman 2001 ) and subsequent disability. EAE is an induced autoimmune disease in mice that mimics a portion of the clinical signs of MS, resulting in inflammatory demyelination of the CNS by encephalitogenic CD4 + T cells specific for CNS autoantigens (Williams et al. 1994) . Women with MS often experience clinical improvement during pregnancy, indicating that sex hormones may hold therapeutic potential in the treatment of MS. Indeed, it has been shown by numerous laboratories that E2 confers potent protection against clinical and histopathological signs of EAE (Daumer et al. 2012) .
Previous studies suggest that B cell deficient mice develop a severe, non-remitting form of EAE (Fillatreau et al. 2002; Wolf et al. 1996) . Supportive of this finding, B cell depletion with anti-CD20 antibody before EAE induction resulted in exacerbation of clinical signs of disease and increased encephalitogenic T cell influx into the CNS (Matsushita et al. 2008) . These studies led to the identification of IL-10 producing CD19 + monocytes (Fig. 6a) ; CD122, on splenic CD8 + T cells (Fig. 6b) ; Foxp3, on splenic CD4 + T cells (Fig. 6c) and PD-1, on splenic CD4 + Foxp3 + regulatory T cells (Fig. 6d) . Data are representative from 4 independent experiments consisting of 6 mice per group (mean±SEM). Statistical analysis was performed with ANOVA followed by Newman-Kuels post hoc test. Significant differences between sample means are indicated (*p≤0.05; **p≤0.01; ***p≤0.001) experimental stroke (Bodhankar et al. 2013a) , indicating a role for B regs in attenuating a range of inflammatory responses.
Our previous work demonstrated that E2-implanted μMT −/− mice developed only transient E2-mediated protection, but reconstitution with wild-type B cells provided significant protection from EAE compared with sham-treated recipients (Bodhankar et al. 2011 ). However, the protection gained through B cell transfers from naïve WT mice was short-lived, with recipients losing protection after day 21 post-EAE induction. In the present study, in order to dissect the interaction of IL-10 + B regs and E2 in neuroprotection, we assessed sham controls, IL-10 + B cell administration alone, E2 implantation alone and the combination of these agents for preventing clinical signs of EAE and reducing CNS inflammation. Additionally, using CNS antigen specific B cells purified from MOG 35-55 -immunized donors and stimulated with LPS to augment IL-10 production, we observed enhanced protection against EAE with delayed or less aggressive onset of disease.
The regulatory function of B cells is considered to be mainly determined by the secretion of IL-10. However, various B cell subsets are capable of IL-10 secretion (Iwata et al. 2011; Kalampokis et al. 2013; Yang et al. 2010) . In order to identify the diversity in the phenotype of IL-10 producing regulatory B cells, evaluation of stimulated B cells used for adoptive transfer showed that approximately 30 % of B cells yielded measurable quantities of IL-10-eGFP conjugate (data not shown (Bodhankar et al. 2013a ). This finding suggests that these cells are exerting an overall immunosuppressive effect in their recipients. Future studies will delineate the contributions to E2 mediated protection of each of these regulatory B cell subsets in ameliorating EAE signs. Regulatory T cells and the co-inhibitory PD-1/PD-L1 signaling pathway have previously been shown to be involved in the E2-conferred protection against EAE in μMT −/− mice (Bodhankar et al. 2013b; Bodhankar et al. 2012) . Our data indicate that the significant increase in percentages of CD4 + Foxp3 + PD-1 + regulatory T cells and up-regulation of PD-1/PD-L1 pathway molecules is a result of co-administration of IL-10 + B cells acting in concert with E2.
Persistent activation of microglia is associated with infiltration of inflammatory cells and neuronal dysfunction in the CNS during EAE (Marques et al. 2006; Rasmussen et al. 2007 ). Thus, we analyzed the phenotypes of microglia/ macrophages found in the CNS of EAE-afflicted μMT −/− mice. Our findings indicate that regulatory B cells in the presence of E2 dramatically attenuate activation of microglia/ macrophages in the CNS during EAE. Whether this effect is due to direct interaction between these cell types or relies on intermediate cellular signaling remains unclear. In vitro examinations of how these populations interact alone and in the presence of powerful endocrine signals such as E2 may be warranted to untangle the involvement of B regs in reducing microglial activation during EAE.
Regulatory B cells modify immune activity by acting as APCs to induce immune tolerance as well as by secreting IL-10 (Bodhankar et al. 2012; Yang et al. 2010 ). Our past findings have shown that MOG-specific B cells obtained from WT donors are not sufficient to sustain E2 mediated protection against EAE long-term in μMT −/− mice (Bodhankar et al. 2012; Bodhankar et al. 2011) . Other reports show that regulatory B cells inhibit EAE initiation in mice while pathogenic B cells promote disease progression (Matsushita et al. 2008; Ray and Basu 2014) . Our current study demonstrates that a small sub-population of B cells enriched in producing IL-10 conferred peripheral and CNS-localized anti-inflammatory effects in mice exposed to pregnancy levels of E2. Hallmarks of these effects include the suppression of microglia/macrophage activation, arrest of leukocyte infiltration into the CNS, activation & differentiation of CD4 + Foxp3 + PD-1 + T regs , and activation of the co-inhibitory PD-1/PD-L1 pathway. Understanding the mechanisms that drive the potent suppressive effects observed after E2/IL-10 + B cell co-administration may expose new targets for pharmaceutical or cell therapy based interventions in multiple sclerosis and other neurodegenerative or neuroinflammatory disorders.
